Status:
UNKNOWN
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
Lead Sponsor:
M Abdur Rahim Medical College and Hospital
Collaborating Sponsors:
First affiliated Hospital Xi'an Jiaoting University
Conditions:
Covid19
Covid-19 ARDS
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease ...
Eligibility Criteria
Inclusion
- Severe COVID-19 patients require hospitalization under HDU/ICU. The SARSCoV-2 infection will be confirmed by RT PCR / CT Chest in every case.
Exclusion
- Participants with uncontrolled clinical status who were hospitalized from the before. Contraindication / possible drug interaction. Participants who have any severe and/or uncontrolled medical conditions like, Severe ischemic heart disease, epilepsy, malignancy, Pulmonary/ renal/hepatic disease, AIDS, Pulmonary TB, pregnancy, Corpulmonale, and etc.
Key Trial Info
Start Date :
September 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 5 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04693026
Start Date
September 10 2020
End Date
March 5 2021
Last Update
January 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh, 5200